Phaseline

Companies › Elicio Therapeutics

Elicio Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ELI-002 7P
Lipid-conjugated CpG oligonucleotide (Amph-CpG-7909) plus lipid-conjugated peptide-based a
KRAS, NRASPhase 1Pancreatic Ductal Adenocarcinoma; Pancreatic CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05726864ELI-002 7PPhase 1Pancreatic Ductal AdenocarcinomaOncologyNov 2026
NCT07671339ELI-002 7PPhase 1Pancreatic CancerOncologyJun 2028

From the company's SEC filings

Cash of $31m on 2026-09-30; operating cash outflow about $40m a year; runway about 9 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KRAS (1) NRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Adlai Nortye Biopharma Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.